Adaptive study of IL-2 dose on regulatory T cells in Type 1 Diabetes (DILT1D)

Trial Profile

Adaptive study of IL-2 dose on regulatory T cells in Type 1 Diabetes (DILT1D)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Oct 2016

At a glance

  • Drugs Aldesleukin (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms DILT1D
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 13 Jun 2014 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network record.
    • 11 Apr 2014 Accrual to date is 115% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top